Sophia Humphreys, PharmD, MHA

Dr Humphreys discusses biosimilar copay programs.

Dr Humphreys discusses pharmacy and provider collaboration.

Dr Humphreys discusses key factors to consider when switching to biosimilars.

Dr Humphreys gives advice for states that require prior prescriber approval for substitution.

Dr. Humphreys discusses operationalizing biosimilars in specialty pharmacies.

Sophia Humphreys, PharmD, MHA, BCBBS, discusses biosimilar utilization and inventory management.

Sophia Humphreys, PharmD, MHA, BCBBS, discusses the key differences between biologics and biosimilars.

The PSJH COVID Workgroup was formed after the concept arose out of the early work of physicians and pharmacists at PSJH.